Lamivudine Experience in Acute Hepatitis B Developing in a Patient Under Chemotherapy

Basit Öğe Kaydı
dc.authoridBal, Tayibe/0000-0002-5315-122X
dc.contributor.authorBal, Tayibe
dc.contributor.authorOnlen, Yusuf
dc.contributor.authorIsitemiz, Feride
dc.contributor.authorKoksaldi-Motor, Vicdan
dc.contributor.authorEvirgen, Omer
dc.contributor.authorKokoglu, Omer Faruk
dc.contributor.authorOcak, Sabahattin
dc.date.accessioned2024-09-18T19:50:20Z
dc.date.available2024-09-18T19:50:20Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAcute hepatitis B (AHB) results 90% in spontaneous healing and often does not require antiviral therapy. It may rarely result in severe liver damage as fulminant hepatitis. The possibility of fulminant hepatitis is high in immunosuppressed patients than in immunocompetent patients. Although the exact cause is unexplained, immunosuppression associated with chemotherapy may increase the possibility of fulminant hepatitis by increasing hepatitis B virus replication in immunosuppressed patients. According to this hypothesis, in immunosuppressed patients with AHB, maintaining viral load suppression with lamivudine therapy may cause less host response and may be effective in preventing risk of fulminant hepatitis. A case in which AHB developed while receiving maintenance chemotherapy for haematological malignancy is presented. Based on similar cases in the literature, the patient was treated with lamivudine and maintenance chemotherapy was continued. In the fourth week of treatment, transaminase levels were normal and anti-HBs was positive. In immunocompromised patients in whom AHB develops, many questions such as the effectiveness of lamivudine treatment, duration of treatment, whether or not to suspend the chemotherapy and when to continue the chemotherapy are still unanswered. Lamivudine experience in this case is reported because there is no guide for this subject in the literature except few case reports.en_US
dc.identifier.doi10.5152/kd.2014.33
dc.identifier.endpage120en_US
dc.identifier.issn1301-143X
dc.identifier.issn1309-1484
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84943389005en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage118en_US
dc.identifier.urihttps://doi.org/10.5152/kd.2014.33
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7363
dc.identifier.volume27en_US
dc.identifier.wosWOS:000420948800008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherAvesen_US
dc.relation.ispartofKlimik Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute hepatitis Ben_US
dc.subjectchemotherapyen_US
dc.subjectlamivudineen_US
dc.titleLamivudine Experience in Acute Hepatitis B Developing in a Patient Under Chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
7363.pdf
Boyut:
56.11 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu